RecruitingNCT07397728

" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus

TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus: A Genotype-Phenotype Correlation Study

Sponsor

South Valley University

Enrollment

90 participants

Start Date

Jun 10, 2025

Study Type

OBSERVATIONAL

Conditions

Systemic Lupus Erythematosus

Summary

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria4

Adult aged 18-60 years
Diagnosed as SLE per 2019 EULAR/ACR classification criteria.
Presence of at least one cutaneous manifestation (acute, subacute, or chronic).
Willing to provide written informed consent for participation and genetic testing

Exclusion Criteria3

Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis).
Systemic infection, malignancy, or pregnancy.
Use of biologic therapy or immunosuppressive pulses within one month.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTTREX1 gene polymorphisms

To assess the prevalence of selected autoantibodies as (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB) and TREX1 gene polymorphisms in SLE patients, and their association with clinical features and disease activity